CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avalo Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avalo Therapeutics Inc
540 Gaither Rd Ste 400
Phone: (410) 522-8707p:410 522-8707 ROCKVILLE, MD  20850-6713  United States Ticker: AVTXAVTX

Business Summary
Avalo Therapeutics, Inc., formerly Cerecor, Inc., is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes targeted therapeutics for patients with clinical need in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates include AVTX-002, AVTX-007, AVTX-006 and AVTX 800 programs. Its AVTX-002 is an Anti-LIGHT mAb targeting immune-inflammatory diseases including acute respiratory distress syndrome (ARDS) and moderate-to-severe inflammatory bowel disease. Its AVTX-007 is an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases including multiple myeloma and Still’s disease. Its AVTX-006 is a dual mTORc1/c2 inhibitor targeting lymphatic malformations. Its AVTX 800 programs include AVTX-801, AVTX-802 and AVTX-803. Its AVTX 800 programs is a therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation (CDGs).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202112/31/2020YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Michael F.Cola 61 6/15/2021 2/3/2020
Chief Financial Officer, Principal Financial Officer, Treasurer SchondGreenway 49 3/1/2021 3/1/2021
Chief Accounting Officer, Principal Accounting Officer ChristopherSullivan 37 3/1/2021 4/24/2020
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Aevi Genomic Medicine, Inc. 435 Devon Park Drive Wayne PA United States

Business Names
Business Name
Aevi Genomic Medicine Europe BVBA/SPRL
Aevi Genomic Medicine, Inc.
AVTX
7 additional Business Names available in full report.

General Information
Number of Employees: 32 (As of 12/31/2020)
Outstanding Shares: 112,317,829 (As of 11/5/2021)
Shareholders: 105
Stock Exchange: NASD
Federal Tax Id: 450705648
Fax Number: (302) 636-5454


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 19, 2022